Small cell carcinoma of the urinary tract: a case report by Kozyrakis, Diomidis et al.
Case report
Open Access












1Department of Urology, “Evagelismos” General Hospital of Athens, Ipsilandou 45-47, 10676, Athens, Greece
2Department of Uropathology, “Evagelismos” General Hospital of Athens, Ipsilandou 45-47, 10676, Athens, Greece
Email: DK* - dkozirakis@yahoo.gr; PP - imonpap@freemail.gr; SS - themisstef@ath.forthnet.gr; EP - epantazis@med.uoc.gr;
AG - agrigorakis@yahoo.com; KP - nelniko@otenet.gr; DM - malovrouvas@evaggelismos-hosp.gr
*Corresponding author
Received: 10 May 2009 Accepted: 19 June 2009 Published: 24 July 2009
Cases Journal 2009, 2:7743 doi: 10.4076/1757-1626-2-7743
This article is available from: http://casesjournal.com/casesjournal/article/view/7743
© 2009 Kozyrakis et al; licensee Cases Network Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Neuroendocrine small cell carcinoma of the urinary tract is rarely encountered and very few cases
have been reported in the literature. Herein we describe a case of small cell malignancy located
contemporarily in the ureter and the bladder.
Introduction
Neuroendocrine small cell carcinoma (SCC) is usually
diagnosed in the lung but its extrapulmonary counterpart
is rarely encountered. The extrapulmonary SCC has been
identified in the gastrointestinal tract, the ear, nose and
throat region, the cervix, the genitourinary tract in men,
the upper respiratory system, the lymphatics, the thymus
and the peritoneum [1,2]. Among the organs of the
genitourinary tract, the most common primary site of the
disease is the bladder, followed by the prostate, the kidney
and the upper urinary tract [1,3].
Small cell carcinoma of the urinary tract is a rare disease.
Herein, we describe one case with SCC located contem-
porarily in the ureter and the bladder.
Case presentation
A 78-year-old Greek male Caucasian presented to the
emergency department due to gross painless intermittent
hematuria. One month before presentation, he observed a
similar symptom but it resolved spontaneously within
24 hours and the patient did not ask for medical
consultation. He used to be a heavy smoker for over
33 years. He suffered from arterial hypertension, diabetes
mellitus type II and prostate hyperplasia and he was under
treatment with lisinopril dihydrate (20 mg once a day),
glimepiride (2 mg twice a day) and tamsulosine hydro-
chloride (0.4 mg per day) respectively. A family history of
neither painless hematuria nor urothelial malignancy has
been referred.
The physical examination was unremarkable. The intrave-
nous urography (IVU) showed a 2 cm-long lesion at the
lower one third of the right ureter (Figure 1). The
cystoscopy identified two tumor sites in the bladder. In
addition, the urine jets coming from the right ureteral
orifice were admixed with blood. Urine cytology was
positive for high grade urothelial cancer. The abdominal
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(Figure 2). Both the abdominal and the chest CT imaging
revealed no signs of distant metastases or lymphatic
involvement.
Transurethral resection of the bladder tumors (Tur-BT)
was initially performed. The postoperative recovery was
uncomplicated and a few days later the patient underwent
right nephroureterectomy with removal of the ipsilateral
bladder cuff. The surgical margins were free of disease.
Macroscopically, a 1.7 cm long, oval-shaped and yellow-
to-pale colored lesion was identified in the ureteral
specimen. The histological examination revealed a neu-
roendocrine small cell carcinoma admixed with a high
grade urothelial carcinoma and with foci of squamous cell
differentiation (Figure 3). In situ carcinoma was also
diagnosed. The lesion extended beyond the ureteral wall,
infiltrating the periureteral fat. The immunohistochemical
staining of the specimen was positive for CD56, synapto-
physin (Syn) and chromogranin (Chr), confirming
the neuroendocrine origin of the tumor (Figure 4). Both
the neuroendorine and the urothelial component of
the carcinoma expressed a 70% positive staining for
Ki-67/MiBi.
The renal parenchyma, the renal pelvis and the upper and
mid ureter were free of disease. The bladder tumors had
similar histological features to those of the ureter but
none of them was infiltrating the muscular layer of the
bladder wall.
Considering the aforementioned clinical and pathological
findings and despite the negative results of the preopera-
tive staging, a thorough investigation of the respiratory
system was performed in order to exclude the lung from
Figure 1. Preoperative IVU showing a filling defect at the
lower one third of the right ureter, proximal hydroureter,
hydronephrosis and ureteral kinking.
Figure 2. Preoperative CT imaging showing a lesion of the
lower one third of the right ureter in close proximity to the
bladder wall.
Figure 3. Pathologic examination of the surgical specimen.
Small cell component of the carcinoma on light microscopy
with H & E staining (×200).
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resolution spiral CT, the bronchoscopy examination, and
the cytology of the sputum, the bronchoalveolar lavage
and the brush specimen were all negative for pulmonary
malignancy.
Postoperatively, renal dysfunction ensued (serum creati-
nine 2.2 mg/dl) and adjuvant chemotherapy (CMT) was
not administered. Within 6 months, distant metastasis
developed in the lung and shortly afterwards the patient
died.
Discussion
As far as we know, only 18 other cases of small cell
carcinoma of the ureter and pelvis (SCC-UP) have been
published in the literature [4-6]. A large series of 10 cases
with SCC of the urinary system has been previously
presented by Chuang & Liao [7].
Risk factors for the disease have not been documented so
far. It is of particular interest the fact that most patients
come from the Far East region [4]. It is unknown weather
environmental conditions, geographic and local factors or
dietary habits predispose to this form of disease.
The role of the uropathologist is of utmost importance
for a correct diagnosis to be established. Histologically,
the SCC-UP is usually admixed with other malignancies,
mainly transitional cell carcinoma (TCC) and rarely with
squamous cell carcinoma, adenocarcinoma and sarcoma
[5,8]. On light microscopy, small cell carcinoma is
consisted of small, round or oval shaped cells, with a
prominent nucleus, scant cytoplasm and granular
chromatin. A high mitotic index may be observed [7,9,10].
In controversial cases, positive immunohistochemical
staining for two or more of the neuroendocrine markers
eg. CD-56, neuron specific enolase (NSE), Syn, Chg, might
contribute to the correct diagnosis [9,10]. We confirmed
positive staining for CD-56, which could also be implicated
in novel targeted-molecular therapies. It has already been
reported that C-kit, EGFR, BCL2 and CD-56 represent
potential targets of molecular therapy and have been
identified immunohistochemically in SCC of the prostate
[10]. A detailed immunohistochemical analysis of the
SCC-UP specimens, with a panel of antibodies against the
aforementioned potential therapeutic targets, has not been
performed so far.
Metastasis to the ureter, originating from a primary SCC of
the lung, although rare, should be excluded during the
diagnostic work up [2]. A lymphoma of the urinary tract
and an undifferentiated urothelial carcinoma (uUC) could
also be confused with the SCC-UP. Leukocyte common
antigen (LCA) and CD44-v6 staining might contribute to
the diagnosis of lymphoma and uUC respectively [9].
The vast majority of SCC-UP patients have at least a
muscle invasive disease at presentation [4-7]. The patient
we are presenting is not an exception, suffering from a
muscle invasive SCC of the ureter and a non muscle
invasive counterpart in the bladder. To our knowledge, no
similar case has been presented in the past.
Surgery (nephroureterectomy or nephrectomy) is the
primary treatment in the majority of SCC-UP patients
but usually cannot achieve adequate control of the disease
[4-7]. In the treatment of SCC of the bladder (SCC-B),
cisplatin-based CMT has been frequently combined with
surgery [2,3]. Mackey et al. [3] published that the
platinum-based chemotherapy is the only statistical
significant factor for improved survival in SCC-B patients
and this finding should be considered in the treatment of
SCC-UP. Radiation therapy alone has rarely been admi-
nistered in SCC patients. It is usually combined with CMT,
but the overall outcome is poor [2].
The lymphatics, the lung, the bones and the liver are
common metastatic sites of the SCC-UP [6]. Generally
speaking, in extrapulmonary SCC, the extent of the disease
determines the survival and should be considered in
determining the prognosis of SCC-UP patients [2].
Vimentin staining might also have a prognostic role. It
has been published that the positive staining is correlated
with high metastatic potential and reduced survival [7].
Conclusion
Irrespectively of the treatment administered, SCC-UP
patients face a dismal prognosis. The majority of them
Figure 4. Immunohistochemical staining of the surgical
specimen. Cytoplasmic expression of CD-56 in the SCC
component (×200).
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Currently, debulking treatment associated with CMT
could offer some survival benefit in selected patients [4].
In the future, targeted molecular therapy might radically
change our therapeutic approach and improve survival of
the patients with rare type of malignancy [10].
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